MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin CancerGlobeNewsWire • 02/22/21
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021GlobeNewsWire • 02/16/21
MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceGlobeNewsWire • 02/10/21
MediWound Provides Progress Update on Its EscharEx Clinical Development ProgramGlobeNewsWire • 01/11/21
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement AgentGlobeNewsWire • 12/21/20
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud GroupGlobeNewsWire • 12/14/20
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Will MediWound (MDWD) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 11/03/20
MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020GlobeNewsWire • 11/02/20
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal BurnsGlobeNewsWire • 09/16/20
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response PreparednessGlobeNewsWire • 08/25/20
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/20
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020GlobeNewsWire • 07/28/20